Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 974
Filter
1.
Eur J Endocrinol ; 185(6): 803-812, 2021 Oct 25.
Article in English | MEDLINE | ID: mdl-34606470

ABSTRACT

OBJECTIVE: Parathyroid carcinoma (PC), atypical parathyroid tumours (APT) and parathyroid adenoma (PA), all present with hypercalcemia. Diminished calcium-sensing receptor (CaSR) expression is reported in PC but is rare in benign tumours. Filamin A (FLNA) binds to the CaSR and activates the mitogen-activated protein kinase (MAPK) signalling pathway. FLNA is related to tumour aggressiveness in several cancers, but its role in parathyroid neoplasia is unknown. DESIGN: We examined FLNA, CaSR and parafibromin expression in PCs (n = 32), APTs (n = 44) and PAs (n = 77) and investigated their potential as diagnostic and/or prognostic markers. METHODS: Tissue microarray slides were immunohistochemically stained with antibodies for FLNA, CaSR and parafibromin. Staining results were correlated with detailed clinical data. RESULTS: All tumours stained positively for CaSR, with two tumours (one PC and one APT) showing diminished expression. Carcinomas were characterized by increased cytoplasmic FLNA expression compared to APTs and PAs (P = 0.004). FLNA expression was not correlated with Ki-67 proliferation index or loss of parafibromin expression. Cytoplasmic FLNA expression was also associated with higher serum calcium, PTH concentrations and male sex (P = 0.014, P = 0.017 and P = 0.049 respectively). Using a combined marker score, we found that parathyroid tumours with low FLNA expression and positive parafibromin staining were extremely likely to be benign (P < 0.001). CONCLUSION: Cytoplasmic and membranous FLNA expression is increased in parathyroid carcinomas compared to benign tumours. A combined FLNA and parafibromin expression score shows potential as a prognostic predictor of indolent behaviour in parathyroid neoplasms.


Subject(s)
Carcinoma/chemistry , Filamins/analysis , Parathyroid Neoplasms/chemistry , Tumor Suppressor Proteins/analysis , Adenoma/chemistry , Adenoma/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Carcinoma/pathology , Female , Finland , Humans , Immunohistochemistry , Male , Middle Aged , Parathyroid Neoplasms/pathology , Prognosis , Receptors, Calcium-Sensing/analysis , Tissue Array Analysis , Young Adult
2.
Asian Pac J Cancer Prev ; 22(10): 3365-3376, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34711014

ABSTRACT

BACKGROUND: The follicular-patterned thyroid lesions (FPTLs) include hyperplastic nodules (HN), follicular adenoma (FA), non-invasive follicular neoplasm with papillary-like nuclear features (NIFTP), follicular carcinoma (FC), and the follicular variant of papillary carcinoma (FVPTC). Sometimes the pathologists cannot accurately separate these lesions from each others on a histological basis. AIMS: To evaluate the utility of immunohistochemistry in the diagnosis of FPTLs. MATERIALS AND METHODS: Immunohistochemical analysis, incorporating 83 cases of histologically confirmed FPTLs out of which 20 carcinomas, 51 benign FPTLs (38 HN and 13 FA), and 12NIFTP were separated from each others using four immunostains (HBME-1, CK19, Galectin-3, and CD56). RESULTS: We found statistically significantly more frequent expression of HBME-1, CK19, Galectin-3 proteins in carcinomas as compared to benign FPTLs (p = <0.01). HBME-1 and Galectin-3 were the most sensitive markers for the diagnosis of malignant FPTLs (75%). Galectin-3 was the most specific marker for the diagnosis of carcinoma (90.3%). CONCLUSIONS: The histomorphological features remain the cornerstone of the diagnosis of FPTN. Although HBME-1, Galectin-3, and CK19 immunostains have some diagnostic value in the separation of malignant from benign FPTLs, they are variably expressed in the benign and malignant FPTLs. No single immunostain has sufficient sensitivity and specificity and therefore their diagnostic use is controversial. Future studies are mandated to find more reliable markers that can separate between benign and malignant FPTLs.


Subject(s)
Adenocarcinoma, Follicular/chemistry , Adenoma/chemistry , Biomarkers, Tumor/analysis , Thyroid Cancer, Papillary/chemistry , Thyroid Neoplasms/chemistry , Thyroid Nodule/chemistry , Adenocarcinoma, Follicular/pathology , Adenoma/pathology , Adolescent , Adult , CD56 Antigen/analysis , Female , Galectin 3/analysis , Humans , Immunohistochemistry , Keratin-19/analysis , Male , Middle Aged , Thyroid Cancer, Papillary/pathology , Thyroid Neoplasms/pathology , Thyroid Nodule/pathology , Young Adult
3.
Diagn Pathol ; 16(1): 86, 2021 Sep 25.
Article in English | MEDLINE | ID: mdl-34563225

ABSTRACT

BACKGROUND: Thyroid tumors are often difficult to histopathologically diagnose, particularly follicular adenoma (FA) and follicular carcinoma (FC). Papillary carcinoma (PAC) has several histological subtypes. Periostin (PON), which is a non-collagenous extracellular matrix molecule, has been implicated in tumor invasiveness. We herein aimed to elucidate the expression status and localization of PON in thyroid tumors. METHOD: We collected 105 cases of thyroid nodules, which included cases of adenomatous goiter, FA, microcarcinoma (MIC), PAC, FC, poorly differentiated carcinoma (PDCa), and undifferentiated carcinoma (UCa), and immunohistochemically examined the PON expression patterns of these lesions. RESULTS: Stromal PON deposition was detected in PAC and MIC, particularly in the solid/sclerosing subtype, whereas FA and FC showed weak deposition on the fibrous capsule. However, the invasive and/or extracapsular regions of microinvasive FC showed quite strong PON expression. Except for it, we could not find any significant histopathological differences between FA and FC. There were no other significant histopathological differences between FA and FC. Although PDCa showed a similar PON expression pattern to PAC, UCa exhibited stromal PON deposition in its invasive portions and cytoplasmic expression in its carcinoma cells. Although there was only one case of UCa, it showed strong PON immunopositivity. PAC and MIC showed similar patterns of stromal PON deposition, particularly at the invasive front. CONCLUSIONS: PON may play a role in the invasion of thyroid carcinomas, particularly PAC and UCa, whereas it may act as a barrier to the growth of tumor cells in FA and minimally invasive FC.


Subject(s)
Adenoma/chemistry , Biomarkers, Tumor/analysis , Carcinoma, Papillary/chemistry , Cell Adhesion Molecules/analysis , Goiter/metabolism , Immunohistochemistry , Thyroid Cancer, Papillary/chemistry , Thyroid Neoplasms/chemistry , Thyroid Nodule/chemistry , Adenoma/pathology , Adolescent , Adult , Aged , Carcinoma, Papillary/pathology , Cell Differentiation , Female , Goiter/pathology , Humans , Male , Middle Aged , Neoplasm Invasiveness , Predictive Value of Tests , Thyroid Cancer, Papillary/pathology , Thyroid Neoplasms/pathology , Thyroid Nodule/pathology , Young Adult
4.
Rev Esp Patol ; 54(3): 206-210, 2021.
Article in English | MEDLINE | ID: mdl-34175035

ABSTRACT

Pulmonary papillary adenoma (PA) is an unusual tumor with only 32 reported cases to date. We present a case of a 69-year-old man, a smoker from the age of 12, with a central mass in the pulmonary left lower lobe identified in a PET-CT scan. Microscopical analysis of the Fine Needle Aspiration (FNA) samples showed fragments of a tumor comprised of abundant papillary structures lined by a monolayer of cytologically bland columnar to cuboidal epithelial cells. The immunohistochemical stains were positive for CK7, TTF-1 and EMA in the epithelial cells, and negative for MYC. Based on the imaging tests, histological features and immunohistochemical profile, the tumor was diagnosed as pulmonary PA. The cytologic and histologic features of this rare entity are described in detail and the value of FNA as an essential presurgical diagnostic procedure is emphasized.


Subject(s)
Adenoma/pathology , Lung Neoplasms/pathology , Rare Diseases/pathology , Adenoma/chemistry , Adenoma/diagnostic imaging , Aged , Biopsy, Fine-Needle , Humans , Incidental Findings , Lung/pathology , Lung Neoplasms/chemistry , Lung Neoplasms/diagnostic imaging , Male , Positron Emission Tomography Computed Tomography , Rare Diseases/diagnostic imaging
5.
Virchows Arch ; 479(3): 551-558, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33768319

ABSTRACT

TERT promoter (TERTp) mutations widely occur in multiple human neoplasms, and they have been related to different clinicopathological features. To date, this mutation has not been identified in sebaceous tumors. Here, we analyzed TERTp mutations in 91 sebaceous neoplasms (17 adenomas, 45 sebaceomas, and 29 carcinomas). We detected mutations in 26.7% (8 of 29) of sebaceous carcinomas by pyrosequencing and Sanger sequencing. No mutation was detected in adenomas or sebaceomas. The difference was significant between sebaceoma and carcinoma. The most frequent TERTp mutations were C228T and C250T in 37.5% (3 of 8) of mutated cases each one. The mutation was not associated with poor clinical evolution. Using NGS, 20 of 29 (68.5%) sebaceous carcinomas harbored mutations in 8 of the 30 genes analyzed (TP53, TERTp, EGFR, ATRX, PDGFRA, CDKN2A, PTEN, and ACVR1). With immunohistochemistry, only 1 of 8 (12.5%) TERTp-mutated carcinomas lacked mismatch repair (MMR) protein expression compared to 6 of 21 (31.6%) of non-mutated ones. Sebaceous carcinomas with MMR protein expression had significantly higher frequency of total mutations and TP53 and TERTp mutations than MMR protein-deficient carcinomas. In conclusion, TERTp mutation has been detected in sebaceous carcinomas, and its presence could be useful to differentiate sebaceous carcinoma from sebaceoma, a difficult histopathological challenge.


Subject(s)
Adenoma/genetics , Biomarkers, Tumor/genetics , Carcinoma/genetics , Mutation , Promoter Regions, Genetic , Sebaceous Gland Neoplasms/genetics , Telomerase/genetics , Adenoma/chemistry , Adenoma/pathology , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Carcinoma/chemistry , Carcinoma/pathology , DNA Mismatch Repair , DNA Mutational Analysis , Female , Genetic Predisposition to Disease , High-Throughput Nucleotide Sequencing , Humans , Immunohistochemistry , Male , Middle Aged , Phenotype , Sebaceous Gland Neoplasms/chemistry , Sebaceous Gland Neoplasms/pathology , Tumor Suppressor Protein p53/genetics
6.
Diagn Pathol ; 16(1): 25, 2021 Mar 17.
Article in English | MEDLINE | ID: mdl-33731149

ABSTRACT

BACKGROUND: Fine-needle aspiration (FNA) is a frequently utilized method for the diagnosis of thyroid nodules. Although the technique has clear advantages, the injury caused by the aspiration needle can induce various histological alterations. Herein, we report a case of follicular adenoma showing histological alterations possibly caused by FNA biopsy. Furthermore, the histological appearance of the lesion mimicked those of medullary thyroid carcinoma, particularly in the frozen section. CASE PRESENTATION: Ultrasonography of a thyroid nodule in a 39-year-old man revealed a mass (2.2 cm in diameter) in the right thyroid lobe. FNA was performed three times on the mass, and the results of the cytology were atypia of undetermined significance. Thereafter, the patient underwent right hemithyroidectomy. The histological findings of the operative frozen section analysis indicated medullary thyroid carcinoma. However, after evaluation and immunohistochemical staining of the permanent section, the mass was diagnosed as follicular adenoma with extensive fibrosis. CONCLUSION: The histological alterations observed in the follicular adenoma are believed to have been caused by injury during the repeated FNA procedures.


Subject(s)
Adenoma/pathology , Biopsy, Fine-Needle/adverse effects , Carcinoma, Neuroendocrine/pathology , Thyroid Neoplasms/pathology , Thyroid Nodule/pathology , Adenoma/chemistry , Adenoma/diagnostic imaging , Adenoma/surgery , Adult , Biomarkers, Tumor/analysis , Carcinoma, Neuroendocrine/chemistry , Fibrosis , Frozen Sections , Humans , Immunohistochemistry , Male , Predictive Value of Tests , Thyroid Neoplasms/chemistry , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/surgery , Thyroid Nodule/chemistry , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/surgery , Thyroidectomy , Ultrasonography
7.
BMC Cancer ; 21(1): 207, 2021 Mar 01.
Article in English | MEDLINE | ID: mdl-33648461

ABSTRACT

BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide; it is the fourth leading cause of death in the world and the third in Brazil. Mutations in the APC, DCC, KRAS and TP53 genes have been associated with the progression of sporadic CRC, occurring at defined pathological stages of the tumor progression and consequently modulating several genes in the corresponding signaling pathways. Therefore, the identification of gene signatures that occur at each stage during the CRC progression is critical and can present an impact on the diagnosis and prognosis of the patient. In this study, our main goal was to determine these signatures, by evaluating the gene expression of paired colorectal adenoma and adenocarcinoma samples to identify novel genetic markers in association to the adenoma-adenocarcinoma stage transition. METHODS: Ten paired adenoma and adenocarcinoma colorectal samples were subjected to microarray gene expression analysis. In addition, mutations in APC, KRAS and TP53 genes were investigated by DNA sequencing in paired samples of adenoma, adenocarcinoma, normal tissue, and peripheral blood from ten patients. RESULTS: Gene expression analysis revealed a signature of 689 differentially expressed genes (DEG) (fold-change> 2, p< 0.05), between the adenoma and adenocarcinoma paired samples analyzed. Gene pathway analysis using the 689 DEG identified important cancer pathways such as remodeling of the extracellular matrix and epithelial-mesenchymal transition. Among these DEG, the ETV4 stood out as one of the most expressed in the adenocarcinoma samples, further confirmed in the adenocarcinoma set of samples from the TCGA database. Subsequent in vitro siRNA assays against ETV4 resulted in the decrease of cell proliferation, colony formation and cell migration in the HT29 and SW480 colorectal cell lines. DNA sequencing analysis revealed KRAS and TP53 gene pathogenic mutations, exclusively in the adenocarcinomas samples. CONCLUSION: Our study identified a set of genes with high potential to be used as biomarkers in CRC, with a special emphasis on the ETV4 gene, which demonstrated involvement in proliferation and migration.


Subject(s)
Adenocarcinoma/genetics , Adenoma/genetics , Colorectal Neoplasms/genetics , Genes, Neoplasm , Neoplasm Proteins/physiology , Proto-Oncogene Proteins c-ets/physiology , Adenocarcinoma/chemistry , Adenocarcinoma/pathology , Adenoma/chemistry , Adenoma/pathology , Aged , Biomarkers, Tumor/genetics , Brazil , Cell Division/genetics , Cell Line, Tumor , Cell Movement/genetics , Cell Transformation, Neoplastic/genetics , Colorectal Neoplasms/chemistry , Colorectal Neoplasms/pathology , DNA, Neoplasm/genetics , Disease Progression , Female , Gene Expression Regulation, Neoplastic , Gene Ontology , Humans , Male , Middle Aged , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/genetics , Proto-Oncogene Proteins c-ets/antagonists & inhibitors , Proto-Oncogene Proteins c-ets/genetics , RNA Interference , RNA, Small Interfering/genetics , RNA, Small Interfering/pharmacology , Tissue Array Analysis , Transcriptome , Tumor Stem Cell Assay
8.
Eur J Endocrinol ; 184(4): 521-531, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33524001

ABSTRACT

OBJECTIVE: Current markers predicting tumour progression of pituitary adenomas after surgery are insufficient. Our objective was to investigate if minichromosome maintenance protein 7 (MCM7) expression predicts tumour progression in non-functioning pituitary adenomas (NFPAs). METHODS: In a cohort study of surgically treated NFPAs, two groups with distinctly different behaviour of a residual tumour were selected: one group requiring reintervention due to tumour progression (reintervention group, n = 57) and one with residual tumours without progression (radiologically stable group, n = 40). MCM7, Ki-67, oestrogen receptor-α expression, mitotic index and tumour subtype were assessed by immunohistochemistry, and their association with tumour progression requiring reintervention was analysed. RESULTS: Median (IQR) MCM7 expression was 7.4% (2.4-15.2) in the reintervention group compared with 2.0% (0.6-5.3) in the radiologically stable group (P <0.0001). Cox regression analysis showed an association between high (>13%) MCM7 expression and reintervention (HR: 3.1; 95% CI:1.7-5.4; P = 0.00012). The probability for reintervention within 6 years for patients with high MCM7 was 93%. Ki-67 expression >3% (P = 0.00062), age ≤55 years (P = 0.00034) and mitotic index≥1 (P = 0.024) were also associated with reintervention. Using a receiver operating characteristics curve, a predictive model for reintervention with all the above predictors yielded an area under the curve of 82%. All eight patients with both high MCM7 and high Ki-67 needed reintervention. CONCLUSION: This cohort study shows that expression of MCM7 is a predictor for clinically significant postoperative tumour progression. Together with age, Ki-67 and mitotic index, MCM7 might be of added value as a predictive marker when managing patients with NFPA after surgery.


Subject(s)
Adenoma/chemistry , Biomarkers, Tumor/analysis , Minichromosome Maintenance Complex Component 7/analysis , Pituitary Neoplasms/chemistry , Adenoma/pathology , Adenoma/surgery , Adult , Aged , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Male , Middle Aged , Mitotic Index , Neoplasm, Residual/chemistry , Neoplasm, Residual/pathology , Neoplasm, Residual/therapy , Pituitary Neoplasms/pathology , Pituitary Neoplasms/surgery , Postoperative Care , Radiotherapy , Reoperation , Sweden
9.
Am J Surg Pathol ; 45(4): 516-522, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33560656

ABSTRACT

We identified an unusual pattern of renal tubular proliferation associated with chronic renal disease, found in 23 patients, diffusely (n=12), or focally (n=11). Incidence was 5% of end-stage renal disease kidneys from one institution (8/177) and 7/23 patients with acquired cystic kidney disease-associated renal cell carcinoma from another. Most (19 patients) had 1 or more neoplasms including papillary (n=9), acquired cystic kidney disease (n=8), clear cell (n=4), or clear cell papillary (n=3) renal cell carcinoma. All (20 men, 3 women) had end-stage renal disease. The predominant pattern (n=18) was the indentation of chronic inflammation into renal tubules forming small polypoid structures; however, 5 had predominantly hyperplastic epithelium with less conspicuous inflammation. In 14 patients both patterns were appreciable, whereas the remainder had only the inflammatory pattern. Immunohistochemistry was positive for cytokeratin 7, high-molecular-weight cytokeratin, PAX8, and GATA3. Staining for alpha-methylacyl-CoA racemase was negative or weak, dramatically less intense than papillary neoplasms or proximal tubules. CD3 and CD20 showed a mixture of B and T lymphocytes in the inflammatory areas. Fluorescence in situ hybridization showed no trisomy 7 or 17 or loss of Y (n=9). We describe a previously uncharacterized form of renal tubular proliferation that differs from papillary adenoma (with weak or negative alpha-methylacyl-CoA racemase, lack of trisomy 7 or 17, and sometimes diffuse distribution). On the basis of consistent staining for high-molecular-weight cytokeratin and GATA3, we propose the name distal tubular hyperplasia for this process. Future studies will be helpful to assess preneoplastic potential and etiology.


Subject(s)
Adenoma/pathology , Carcinoma, Renal Cell/pathology , Cell Proliferation , Kidney Diseases, Cystic/pathology , Kidney Failure, Chronic/pathology , Kidney Neoplasms/pathology , Kidney Tubules/pathology , Precancerous Conditions/pathology , Adenoma/chemistry , Adenoma/genetics , Adult , Aged , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Carcinoma, Renal Cell/chemistry , Carcinoma, Renal Cell/genetics , Diagnosis, Differential , Female , Humans , Hyperplasia , Immunohistochemistry , In Situ Hybridization, Fluorescence , Kidney Diseases, Cystic/genetics , Kidney Diseases, Cystic/metabolism , Kidney Failure, Chronic/genetics , Kidney Failure, Chronic/metabolism , Kidney Neoplasms/chemistry , Kidney Neoplasms/genetics , Kidney Tubules/chemistry , Male , Middle Aged , Precancerous Conditions/genetics , Precancerous Conditions/metabolism , Predictive Value of Tests , United States , Young Adult
10.
J Pathol Clin Res ; 7(3): 287-300, 2021 05.
Article in English | MEDLINE | ID: mdl-33400370

ABSTRACT

We collected 26 cases of bronchiolar adenoma (BA) and its variants, and performed a comprehensive characterization using a combination of morphological, immunohistochemical, and genetic assessments. Of these 26, 13 were classic bilayered cases, including 10 proximal and 3 distal-type BAs. Of note, we also identified 13 cases that lacked a continuous basal cell layer. In five cases, the adenomas were partially classic bilayered, leaving a single layer of columnar or cuboidal epithelial cells in some areas of the lesion (BA with monolayered cell lesions). In the other eight cases, the glandular or papillary structures were entirely composed of monolayered columnar or cuboidal epithelial cells, which were morphologically identical to the luminal epithelial cells of classic BA (monolayered BA-like lesions). Immunohistochemical analysis revealed thyroid transcription factor 1 expression by ciliated columnar epithelial cells, basal cells, and nonciliated columnar and cuboidal epithelial cells. Basal cells also expressed p40 and p63. Twenty-five cases underwent next-generation sequencing using a 422-cancer-gene panel (GeneseeqPrime). Oncogenic driver mutations were detected in 23 cases, including 13 (52%) with EGFR mutations, 4 (16%) with KRAS G12D/V mutations, 3 (12%) with BRAF V600E mutations, 2 (8%) with ERBB2 exon 20 insertions, and 1 (4%) with a RET fusion. EGFR exon 20 insertions were present in 100% of BAs with monolayered cell lesions, 37.5% of monolayered BA-like lesions, and 8% of classic BA (Fisher's exact test, p = 0.002, false discovery rate = 0.014). Collectively, our study revealed a gradual morphological transition between BA and its variants. The genetic composition of BAs with monolayered structures differed significantly from those of classic BAs or lung adenocarcinoma.


Subject(s)
Adenoma , Biomarkers, Tumor , Bronchial Neoplasms , Immunohistochemistry , Molecular Diagnostic Techniques , Adenoma/chemistry , Adenoma/genetics , Adenoma/pathology , Adult , Aged , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Biopsy , Bronchial Neoplasms/chemistry , Bronchial Neoplasms/genetics , Bronchial Neoplasms/pathology , DNA Mutational Analysis , Diagnosis, Differential , Female , Gene Fusion , High-Throughput Nucleotide Sequencing , Humans , In Situ Hybridization , Male , Middle Aged , Mutation , Predictive Value of Tests , Retrospective Studies
12.
Am J Dermatopathol ; 43(2): 93-102, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-32568835

ABSTRACT

ABSTRACT: Extraocular sebaceous carcinoma (ESC) is a rare appendiceal skin tumor. In contrast to ocular sebaceous carcinoma, information about the exact cellular architecture of these lesions is scarce and the histogenesis of ESC is unknown. Here, we extend our previous study and investigate 28 extraocular carcinomas in comparison to 54 benign sebaceous tumors and 8 cases of normal sebaceous glands using a broad spectrum of antibodies against p63, several keratins, adipophilin, EMA, Ki67, androgen receptor, and mismatch repair proteins. This observational study demonstrates that p63- and K5/14-positive basaloid cells are key cells in normal sebaceous gland and in all sebaceous tumors and that these basaloid cells give rise to EMA+, adipophilin+ sebocytes, and K5/14+, K7±, K10± ductal structures. Finally, about half of ESC is associated with superficial in situ neoplasia, which provides evidence that at least part of these carcinomas arises from flat superficial in situ carcinoma. In contrast to the normal sebaceous gland, about half of all sebaceous tumors lack keratin K7. MMR protein IHC-profiles role will be discussed.


Subject(s)
Adenoma/chemistry , Biomarkers, Tumor/analysis , Carcinoma/chemistry , Immunohistochemistry , Sebaceous Gland Neoplasms/chemistry , Adenoma/pathology , Adult , Aged , Aged, 80 and over , Biopsy , Carcinoma/pathology , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Sebaceous Gland Neoplasms/pathology
13.
Virchows Arch ; 478(2): 201-207, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32583014

ABSTRACT

This study aims to investigate the utility of digital protocols for Ki-67 immunohistochemistry quantitative analysis ("hot spot" method) in the setting of well-differentiated hepatocellular neoplasms. Resection cases of typical hepatic adenomas (HAs) (n = 40), atypical HAs (n = 9), and well-differentiated hepatocellular carcinomas (WD HCCs) (n = 56) were selected. HAs were further classified by immunohistochemistry using antibodies against liver fatty acid binding protein, glutamine synthetase, B-catenin, hepatic serum amyloid A, and C-reactive protein. Ki-67 proliferative index by immunohistochemistry was evaluated in all cases by digital analysis using a modified neuroendocrine tumor "hot spot" protocol. The proliferative rate of HAs (typical, median 1.2% (range 0-7.4%) and atypical, median 1.0% (range 0.3-3%)) was significantly lower than that of WD HCCs (median 4.5%, range 0-49.8%) (P < 0.0001). Only a few (7.5%) of the adenomas (all inflammatory/telangiectatic type) had proliferative rates higher than 4%, compared to most (51%) of HCCs. Ki-67 is a potentially useful adjunct marker in the evaluation of WD hepatocellular neoplasms, as "hot spot" proliferative rates are consistently very low in HAs but vary significantly in WD HCCs.


Subject(s)
Adenoma/chemistry , Carcinoma, Hepatocellular/chemistry , Cell Differentiation , Cell Proliferation , Immunohistochemistry , Ki-67 Antigen/analysis , Liver Neoplasms/chemistry , Microscopy , Adenoma/pathology , Adenoma/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Child , Diagnosis, Differential , Female , Humans , Image Interpretation, Computer-Assisted , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Male , Middle Aged , Predictive Value of Tests , Reproducibility of Results , Young Adult
14.
Virchows Arch ; 478(2): 355-360, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32506155

ABSTRACT

Female adnexal tumor of probable Wolffian origin is a rare tumor listed in the 2016 WHO classification of the female reproductive tract. It does not have a WHO-recognized counterpart in the male urogenital tract. However, some cases of male adnexal tumors have been described in the literature. We present the case of a 41-year-old male who presented with a 2-cm nodule in the testicle. LDH, HCG, and AFP blood levels were normal. Gross examination showed an intratesticular, whitish, microcystic, firm, and encapsulated nodule of 2 cm. Microscopically, the tumor was well circumscribed, solid, and microcystic. In the solid areas, cells were fusiform or polygonal with an eosinophilic pale cytoplasm and a regular oval nucleus. Cysts were surrounded by a fibromuscular stroma and lined by a single layer of cylindrical epithelium, with apical cilia. On immunohistochemistry, tumor cells expressed AE1/AE3 and vimentin and were negative for calretinin, epithelial membrane antigen (EMA), and inhibin. All the differential diagnoses at this localization being ruled out, the tumor was compared to a female adnexal tumor of probable Wolffian origin. Both tumors had approximately the same morphological and immunohistochemical profile. Naming our tumor MATPWO is therefore justified, but it remains of a probable origin because further studies need to be performed in order to certify this hypothesis.


Subject(s)
Adenoma/pathology , Adnexal Diseases/pathology , Testicular Neoplasms/pathology , Adenoma/chemistry , Adenoma/genetics , Adenoma/surgery , Adnexal Diseases/genetics , Adnexal Diseases/surgery , Adult , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , DNA Mutational Analysis , Diagnosis, Differential , Humans , Immunohistochemistry , Male , Mutation , Orchiectomy , Predictive Value of Tests , Testicular Neoplasms/chemistry , Testicular Neoplasms/genetics , Testicular Neoplasms/surgery , Tumor Burden
15.
Br J Radiol ; 93(1113): 20200321, 2020 Sep 01.
Article in English | MEDLINE | ID: mdl-32628097

ABSTRACT

OBJECTIVE: Pituitary macroadenomas (PAs) are usually defined as benign intracranial tumors. However, they may present local aggressive course. High Ki67 labelling index (LI) values have been related to an aggressive tumor behavior. A recent clinicopathological classification of PA based on local invasiveness and proliferation indexes, divided them in groups with different prognosis. We evaluated the utility of conventional MRI (cMRI) and diffusion-weighted imaging (DWI), in predicting the Ki67- LI according the clinicopathological classification. METHODS: 17 patients (12 M and 5 F) who underwent surgical removal of a PA were studied. cMRI features, quantification of T1W and T2W signal intensity, degree of contrast uptake (enhancement ratio, ER) and apparent diffusion coefficient (ADC) values were evaluated by using a 3 T scan. Statistics included Mann-Whitney test, Spearman's test, and receiver operating characteristic analysis. A value of p ≤ 0.05 was considered significant for all the tests. RESULTS: Negative correlations were observed between Ki-67 LI, ADCm (ρ = - 0.67, p value = 0.005) and ER values (ρ = -0.62; p = 0.008). ER values were significantly lower in the proliferative PA group (p = 0.028; p = 0.017). ADCm showed sensitivity and specificity of 90 and 85% respectively into predict Ki67-LI value. A value of ADCm ≤0, 711 x 10-6 mm2 emerged as a cut-off of a value of Ki67-LI ≥ 3%. CONCLUSION: Adding quantitative measures of ADC values to cMRI could be used routinely as a non-invasive marker of specific predictive biomarker of the proliferative activity of PA. ADVANCES IN KNOWLEDGE: Routinely use of DWI on diagnostic work-up of pituitary adenomas may help in establish the likely biological aggressive lesions.


Subject(s)
Adenoma/diagnostic imaging , Ki-67 Antigen/analysis , Magnetic Resonance Imaging/methods , Pituitary Neoplasms/diagnostic imaging , Adenoma/chemistry , Adenoma/pathology , Adenoma/surgery , Cell Nucleus/chemistry , Cell Proliferation , Diffusion Magnetic Resonance Imaging/methods , Diffusion Tensor Imaging/methods , Female , Humans , Male , Middle Aged , Neoplasm Grading/methods , Neoplasm Invasiveness , Pituitary Neoplasms/chemistry , Pituitary Neoplasms/pathology , Pituitary Neoplasms/surgery , ROC Curve , Sensitivity and Specificity , Statistics, Nonparametric
16.
Virchows Arch ; 477(5): 739-742, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32307573

ABSTRACT

Pulmonary pleomorphic adenoma (PA) is a rare salivary gland-type neoplasm, which predominantly occurs in the proximal airway. Rearrangement of the pleomorphic adenoma gene 1 (PLAG1) is the most frequent genetic event in PAs of salivary glands. However, whether pulmonary PA also harbors PLAG1 rearrangement has not been elucidated. Here, we present a case of pulmonary PA, located at the middle lobar bronchus, in a 54-year-old man. CTNNB1-PLAG1 gene fusion was identified by reverse transcription-polymerase chain reaction using formalin-fixed paraffin-embedded tissue (FFPE). Furthermore, immunohistochemical analysis revealed nuclear expression of PLAG1 in all tumor cells. To the best of our knowledge, this is the first reported case of pulmonary PA with CTNNB1-PLAG1 fusion and PLAG1 expression. Our case illustrates the possibility that pulmonary PA could be underpinned by recurrent PLAG1 translocations akin to salivary gland PA.


Subject(s)
Adenoma/genetics , Biomarkers, Tumor/genetics , DNA-Binding Proteins/genetics , Gene Fusion , Lung Neoplasms/genetics , beta Catenin/genetics , Adenoma/chemistry , Adenoma/pathology , Adenoma/surgery , Biomarkers, Tumor/analysis , DNA-Binding Proteins/analysis , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Lung Neoplasms/chemistry , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , Phenotype , Reverse Transcriptase Polymerase Chain Reaction
17.
Minerva Gastroenterol Dietol ; 66(3): 208-210, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32218423

ABSTRACT

BACKGROUND: The P38-protein is known to be expressed in colorectal adenomas (CRA). Expression in low- and high-grade tubular adenomas is decreased when compared to adenocarcinomas and increased with regard to normal mucosa. We aimed to study P38 expression in human CRAs and the relationships to cell proliferation Ki67-protein, stem-phenotype CD133-protein and, to mTOR-protein (AKT pathway). METHODS: The immunohistochemical expression of P38 was evaluated in CRAs on tissue microarrays. Data were analyzed with the Kendall-rank-correlation test. RESULTS: Nuclear P38 correlated to low-grade dysplasia (Kendall P<0.01/tau=-0.254) and to decreased adenoma size (P<0.01/tau=-0.267). Nuclear P38 also correlated to cytoplasmic or membrane mTOR (P<0.01/tau=-0.223 and P<0.01/tau=-0.340) and to cytoplasmic CD133 (P<0.01/0.293). An inverse relationship was observed to Ki67 (P<0.00/ tau=-0.110). CONCLUSIONS: Our results suggest an interference of P38 with initial steps of colorectal adenomagenesis. The correlation to mTOR suggests a biological crosstalk between the MAPK- and AKT-signaling-pathways in colorectal adenomagenesis at P38 level.


Subject(s)
AC133 Antigen , Adenoma , Cell Proliferation , Colorectal Neoplasms , Ki-67 Antigen , TOR Serine-Threonine Kinases , p38 Mitogen-Activated Protein Kinases , AC133 Antigen/physiology , Adenoma/chemistry , Adenoma/genetics , Adenoma/metabolism , Adenoma/pathology , Colorectal Neoplasms/chemistry , Colorectal Neoplasms/genetics , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Female , Humans , Ki-67 Antigen/physiology , Male , Phenotype , Signal Transduction , TOR Serine-Threonine Kinases/physiology , p38 Mitogen-Activated Protein Kinases/analysis , p38 Mitogen-Activated Protein Kinases/biosynthesis
18.
Hum Pathol ; 97: 103-111, 2020 03.
Article in English | MEDLINE | ID: mdl-31783043

ABSTRACT

The molecular alterations identified among pyloric gland adenomas (PGAs) in the published literature are based on polymerase chain reaction of targeted genes, and next-generation sequencing (NGS) has not been performed. In this study, we performed NGS and correlated the molecular alterations with the histologic grade of dysplasia and immunohistochemical findings in a cohort of PGAs. Successful DNA extraction and sequencing were performed in 15 pyloric gland adenomas/adenocarcinoma from 12 patients. Additionally, 4 specimens of autoimmune gastritis were selected to serve as the control group. Ten PGAs with low-grade dysplasia were seen to have mutations in the triad of APC, KRAS, and GNAS genes. Five PGAs with high-grade dysplasia/adenocarcinoma exhibited mutations in several genes including APC, CTNNB1, KRAS, GNAS, TP53, CDKN2A, PIK3CA, and EPHA5 genes but did not exhibit mutations in the triad of APC, KRAS, and GNAS genes. The median tumor mutational burden was higher in PGAs with high-grade dysplasia/adenocarcinoma when compared with PGAs with low-grade dysplasia (5.25 and 4.38, respectively). PGAs with high-grade dysplasia/adenocarcinoma had more chromosomal gains and losses than PGAs with low-grade dysplasia. The molecular findings suggest that there are 2 separate mutator pathways of dysplasia development in PGAs.


Subject(s)
Adenocarcinoma/genetics , Adenoma/genetics , Biomarkers, Tumor/genetics , DNA Mutational Analysis , Gastric Mucosa/pathology , High-Throughput Nucleotide Sequencing , Mutation , Stomach Neoplasms/genetics , Adenocarcinoma/chemistry , Adenocarcinoma/pathology , Adenoma/chemistry , Adenoma/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Grading , Phenotype , Predictive Value of Tests , Stomach Neoplasms/chemistry , Stomach Neoplasms/pathology
19.
Rev Esp Patol ; 52(4): 256-259, 2019.
Article in Spanish | MEDLINE | ID: mdl-31530410

ABSTRACT

Ectopic pituitary adenoma is a rare entity that is most commonly located in the sphenoid sinus. We report a case of a patient with ectopic pituitary adenoma with no functional expression associated with empty sella turcica, which gives rise to a broad differential diagnosis. Although it is a benign neoplasm, necrosis is encountered in a proportion of cases. Magnetic resonance imaging is the diagnostic method of choice for hypothalamic-pituitary-related endocrine diseases with endoscopic biopsy for histological confirmation. It is important to include pituitary markers in the immunohistochemical diagnostic panel.


Subject(s)
Adenoma/diagnostic imaging , Choristoma/diagnostic imaging , Empty Sella Syndrome/etiology , Paranasal Sinus Neoplasms/diagnostic imaging , Pituitary Neoplasms/diagnostic imaging , Sphenoid Sinus/diagnostic imaging , Adenoma/chemistry , Adenoma/pathology , Adenoma/surgery , Adult , Biomarkers, Tumor/analysis , Choristoma/metabolism , Choristoma/pathology , Choristoma/surgery , Diagnosis, Differential , Diagnostic Errors , Empty Sella Syndrome/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Neoplasm Proteins/analysis , Neuroendocrine Tumors/diagnosis , Osteolysis/etiology , Paranasal Sinus Neoplasms/chemistry , Paranasal Sinus Neoplasms/pathology , Paranasal Sinus Neoplasms/surgery , Pituitary Hormones, Anterior/analysis , Pituitary Neoplasms/chemistry , Pituitary Neoplasms/pathology , Pituitary Neoplasms/surgery , Sphenoid Sinus/chemistry , Sphenoid Sinus/pathology , Sphenoid Sinus/surgery
20.
J Mol Neurosci ; 69(3): 399-410, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31280474

ABSTRACT

Pituitary adenomas are the most common intrasellar tumors. Patients should be identified at an early stage so that effective treatment can be implemented. The study aims at detecting the potential biomarkers with diagnostic value of pituitary adenomas. Using a total of seven gene expression profiles (GEPs) of the datasets from the Gene Expression Omnibus (GEO) database, we first screened 1980 significant differentially expressed genes (DEGs). Then, we employed the prediction analysis for microarray (PAM) algorithm to identify 340 significant DEGs able to differ pituitary tumor from normal samples, which include 208 upregulated DEGs and 132 downregulated DEGs. DAVID database was used to carry out the enrichment analysis on Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathways. We found that upregulated candidates were enriched in protein folding and metabolic pathways. Downregulated DEGs saw a significant enrichment in insulin receptor signaling pathway and hedgehog signaling pathway. Based on the protein-protein interaction (PPI) network as well as module analysis, we determined ten hub genes including PHLPP, ENO2, ACTR1A, EHHADH, EHMT2, FOXO1, DLD, CCT2, CSNK1D, and CETN2 that could be potential biomarkers with diagnostic value in pituitary adenomas. In conclusion, the study contributes to reliable and potential molecular biomarkers with diagnostic value. Moreover, these potential biomarkers may be used for prognosis and new therapeutic targets for the pituitary adenomas.


Subject(s)
Adenoma/chemistry , Biomarkers, Tumor/analysis , Pituitary Neoplasms/chemistry , Adenoma/diagnosis , Adenoma/genetics , Algorithms , Biomarkers, Tumor/genetics , Databases, Genetic , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Gene Ontology , Humans , Neoplasm Proteins/analysis , Neoplasm Proteins/genetics , Neoplasm Proteins/physiology , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/genetics , Tissue Array Analysis , Transcription Factors/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...